Matrix metalloproteinase-activated doxorubicin prodrugs inhibit HT1080 xenograft growth better than …
Daniel Hu
Molecular cancer therapeutics
View PDFchevron_right
Discovery of matrix metalloproteases selective and activated peptide–doxorubicin prodrugs as anti-tumor agents
Shu-Yun Zhang, Swamy Yeleswaram, Melody Diamond
Bioorganic & Medicinal Chemistry Letters, 2010
View PDFchevron_right
A New Approach for the Treatment of Malignant Melanoma: Enhanced Antitumor Efficacy of an Albumin-binding Doxorubicin Prodrug That Is Cleaved by Matrix Metalloproteinase 21
AHmed Mansour
2000
View PDFchevron_right
A new approach for the treatment of malignant melanoma: enhanced antitumor efficacy of an albumin-binding doxorubicin prodrug that is cleaved by matrix metalloproteinase 2
Ahmed Mansour
Cancer research, 2003
View PDFchevron_right
Paradoxical Stimulation of Matrix Metalloproteinase-9 Expression in HT1080 Cells by a Broad-Spectrum Hydroxamate-Based Matrix Metalloproteinase Inhibitor
E. Maquoi
Annals of the New York Academy of Sciences, 1999
View PDFchevron_right
Development of matrix metalloproteinase inhibitors in cancer therapy
Michelle Rudek
Hematology/Oncology Clinics of North America, 2002
View PDFchevron_right
New approaches to selectively target cancer-associated matrix metalloproteinase activity
Marilena Tauro
Cancer and Metastasis Reviews, 2014
View PDFchevron_right
Critical appraisal of the use of matrix metalloproteinase inhibitors in cancer treatment
Wen-Tien Chen
Oncogene, 2000
View PDFchevron_right
Inhibition of metalloproteinases derived from tumours: New insights in the treatment of human glioblastoma
Elisa Nuti, Elisabetta Orlandini, Armando Rossello
2010
View PDFchevron_right
Matrix-metalloproteinases as targets for controlled delivery in cancer: An analysis of upregulation and expression
Kyle Isaacson
Journal of Controlled Release, 2017
View PDFchevron_right
A matrix metalloproteinase 2 cleavable melittin/avidin conjugate specifically targets tumor cells in vitro and in vivo
Lori Holle
International Journal of Oncology, 2003
View PDFchevron_right
Tumour microenvironment — Opinion: Validating matrix metalloproteinases as drug targets and anti-targets for cancer therapy
Oded Kleifeld
Nature Reviews Cancer, 2006
View PDFchevron_right
Matrix metalloproteinase and its drug targets therapy in solid and hematological malignancies: An overview
Kanjaksha Ghosh
Mutation Research/Reviews in Mutation Research, 2013
View PDFchevron_right
Anticancer activity of PEGylated matrix metalloproteinase cleavable peptide-conjugated adriamycin against malignant glioma cells
Young-Il Jeong
International journal of pharmaceutics, 2010
View PDFchevron_right
Matrix Metalloproteinase Inhibitors as Anticancer Therapeutics
Ferdinando Mannello
Current Cancer Drug Targets, 2005
View PDFchevron_right
Stimulation of Matrix Metalloproteinase-9 Expression in Human Fibrosarcoma Cells by Synthetic Matrix Metalloproteinase Inhibitors
Charles Lambert, Carine Munaut
Experimental Cell Research, 2002
View PDFchevron_right
A phase I dose escalation study of the matrix metalloproteinase inhibitor BAY 12-9566 administered orally in patients with advanced solid tumours
I. Elias
Annals of oncology : official journal of the European Society for Medical Oncology / ESMO, 2000
View PDFchevron_right
Small-molecule anticancer compounds selectively target the hemopexin domain of matrix metalloproteinase-9
CEM KUSCU
Cancer research, 2011
View PDFchevron_right
Anti-Invasive, Antitumoral, and Antiangiogenic Efficacy of a Pyrimidine-2,4,6-trione Derivative, an Orally Active and Selective Matrix Metalloproteinases Inhibitor
Nor Sounni
Clinical Cancer Research, 2004
View PDFchevron_right
Inhibition of Angiogenesis and Metastasis In Two Murine Models by the Matrix Metalloproteinase Inhibitor, BMS-275291
Joseph Fargnoli
Cancer research, 2001
View PDFchevron_right
Ensnaring membrane type 1-matrix metalloproteinase (MT1-MMP) with tissue inhibitor of metalloproteinase (TIMP)-2 using the haemopexin domain of the protease as a carrier: a targeted approach in cancer inhibition
Huee Lee
Oncotarget
View PDFchevron_right
In Vitro Efficacy of a Sterically Stabilized Immunoliposomes Targeted to Membrane Type 1 Matrix Metalloproteinase (MT1-MMP)
Tatsuhiro Ishida
Biological & Pharmaceutical Bulletin, 2007
View PDFchevron_right
Matrix metalloproteinase inhibitors: Applications in oncology
D. Yip
Investigational New Drugs, 1999
View PDFchevron_right
A novel and selective membrane type-1 matrix metalloproteinase (MT1-MMP) inhibitor reduces cancer cell motility and tumor growth
Tuula Salo
Cancer Biology & Therapy, 2009
View PDFchevron_right
Data from Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis
nicolas frans
View PDFchevron_right
Selective Inhibition of Matrix Metalloproteinase-14 Blocks Tumor Growth, Invasion, and Angiogenesis
nicolas frans
Cancer Research, 2009
View PDFchevron_right
Modulation of Tumor Cell Growth In Vivo by Extracellular Matrix Metalloprotease Inducer
William Grizzle
Archives of Otolaryngology–Head & Neck Surgery, 2008
View PDFchevron_right
CD10 is a key enzyme involved in the activation of tumor-activated peptide prodrug CPI-0004Na and novel analogues: implications for the design of novel peptide prodrugs for the therapy of CD10+ tumors
Dana Buckman
Cancer research, 2003
View PDFchevron_right
Matrix metalloprotease selective peptide substrates cleavage within hydrogel matrices for cancer chemotherapy activation
Syed Salman Lateef
Peptides, 2008
View PDFchevron_right
Matrix metalloproteinases in cancer: from new functions to improved inhibition strategies
luis sanchez
International Journal of Developmental Biology, 2004
View PDFchevron_right
Functional Analysis of Matrix Metalloproteinases and Tissue Inhibitors of Metalloproteinases Differentially Expressed by Variants of Human HT-1080 Fibrosarcoma Exhibiting High and Low Levels of Intravasation and Metastasis
Elena Deryugina
Journal of Biological Chemistry, 2007
View PDFchevron_right